CAICaris Life Sciences, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet, but big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$27.2M, 90 days to Oct 8, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -63% · now 10% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can CAI take a bad year?
Caris Life Sciences, Inc. carries $291M of net debt at 1.67× EBITDA: a load its earnings can carry.
Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 1.67×
Net debt / EBITDA
- Altman Z-score
- 4.40
Altman Z-score · safe zone, above 3
- Interest cover
- 3.27×
Interest cover · operating profit covers the interest bill, with room to spare
Details›
- Total debtQ2 2026
- $393M
- Cash and short-term investments
- $102M
- Net debt
- $291M
- EBITDA, trailing twelve months
- $174M
- Operating profit, trailing twelve months
- $153M
- Debt / equity
- 0.66×
- Total debt / EBITDA
- 2.26×
- Annualised volatilitytwo years of daily moves
- 66%
- Worst drawdown on file
- −63%
- Below its 52-week high
- 10.0%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry